George Savvidis
iPSC Research & Development Thymmune Therapeutics
Seminars
Wednesday 9th September 2026
De-Risking iPSC Cell Line Selection to Enable Clinical Progression & Regulatory Readiness
1:10 pm
- Establishing practical criteria for selecting genomically stable and clinically fit iPSC lines suitable for FDA-bound programs
- Applying updated cell line selection strategies to reduce downstream CMC, comparability, and regulatory risk
- Locking in early decisions that prevent costly reselection, re-qualification, and delays to clinical timelines
